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Abstract
Background: The objectives of this study were to evaluate the effects of two commercial feed supplements,
Egusin 250® [E-250] and Egusin SLH® [E-SLH], on gastric ulcer scores, gastric fluid pH, and blood gas values in stall-
confined horses undergoing feed-deprivation.
Methods: Nine Thoroughbred horses were used in a three-period crossover study. For the three treatment groups,
sweet feed was mixed with E-250, E-SLH, or nothing (control group) and fed twice daily. Horses were treated for
21 days, then an additional 7 days while on an alternating feed-deprivation model to induce or worsen ulcers
(period one). In periods two and three, horses (n=6) were treated for an additional 7 days after feed-deprivation.
Gastroscopies were performed on day -1 (n=9), day 21 (n=9), day 28 (n=9) and day 35 (n=6). Gastric juice pH was
measured and gastric ulcer scores were assigned. Venous blood gas values were also measured.
Results: Gastric ulcers in control horses significantly decreased after 21 days, but there was no difference in ulcer
scores when compared to the Egusin® treated horses. NG gastric ulcer scores significantly increased in E-250 and
control horses on day 28 compared to day 21 as a result of intermittent feed-deprivation, but no treatment effect
was observed. NG ulcer scores remained high in the control group but significantly decreased in the E-SLH- and E-
250-treated horses by day 35. Gastric juice pH values were low and variable and no treatment effect was observed.
Mean blood pCO2 values were significantly increased two hours after feeding in treated horses compared to
controls, whereas mean blood TCO2 values increased in the 24 hour sample, but did not exceed 38 mmol/l.
Conclusions: The feed-deprivation model increased NG gastric ulcer severity in the horses. However, by day 35,
Egusin® treated horses had less severe NG gastric ulcers compared to untreated control horses. After 35 days,
Egusin® products tested here ameliorate the severity of gastric ulcers in stall-confined horses after feed stress.
Background
Nonglandular (NG) gastric ulcers, as part of the equine
gastric ulcer syndrome (EGUS), are common in perfor-
mance horses, and the current FDA-approved pharmaceu-
tical agent in the United States, omeprazole (GastroGard®
paste, Merial Limited, Decatur, GA, USA), is effective in
treatment [1-16]. However, pharmaceutical agents are
expensive, require a prescription, must be administered
orally, and gastric ulcer recurrence is common once treat-
ment is discontinued [15-17]. Development of a less
expensive and natural alternative that could be added to
the feed would be desirable.
Recently, there has been increased interest in the use of
feed supplements to treat and prevent gastric ulcers in
horses, and many commercial products are available
[18-20]; however, little data exists on the efficacy of these
supplements. Two such commercially available feed sup-
plements containing dried apple pectin pulp and other
fruit products, lecithin, sodium bicarbonate, calcium
bicarbonate, dehydrated alfalfa meal, insoluble oat fiber
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(ß-glucan), polar lipids, and natural antioxidants (Egusin
250® (E-250) and Egusin SLH® (E-SLH), Centaur Animal
Health, Overland Park, KS, USA) are commercially avail-
able as aids in promoting a healthy stomach and as aids
in preventing the destruction of the stomach lining (man-
ufacturer claim) [21]. Several ingredients in these feed
supplements been shown in other species to support and
protect the stomach lining, support normal digestive
function, bind bile acids, and protect the stomach against
the generation of damaging oxygen free radicals
[19,20,22-26]. In addition, antacids like calcium carbo-
nate have been shown to protect the nonglandular (NG)
mucosa in vitro from the damaging effects gastric acids
[27,28]; however, there are no critical studies on the use
of this commercial supplements in horses.
The purpose of this study was to evaluate the effect of
E-SLH powder and E-250 pellets on NG gastric ulcer
scores, gastric juice pH, and blood gas values in stall-
confined horses undergoing feed deprivation. We
hypothesize that E-SLH- and E-250-treated horses will
have less severe NG gastric ulcers, higher gastric juice
pH, and similar blood gas values compared to untreated
control horses.
Methods
All procedures were approved by the Louisiana State
University (LSU) Institutional Animal Care and Use
Committee (LSU IACUC Protocol #10-078). All horses
used in the study were Thoroughbred or Thoroughbred-
cross breeds (n=9; 4-11 years of age, 5 geldings & 4
mares, 429-593 kg body weight) from the resident Equine
Health Studies Program (EHSP) herd at LSU School of
Veterinary Medicine. The study was performed in the fall
and winter, from September 23, 2010 through February
15, 2011. Before the beginning of the study, a physical
examination was performed on all horses in order to
exclude presence of clinical disease. All horses were vac-
cinated in the spring for Eastern Equine Encephalitis,
Western Equine Encephalitis, West Nile Virus Encephali-
tis, Tetanus, and Influenza and dewormed with a product
containing ivermectin or moxidectin (200 μg/kg body
weight, orally, twice yearly) as part of the routine herd
care. For period 1 of the study, horses enrolled were stra-
tified by equine gastric ulcer syndrome (EGUS) score
[15] as recorded on day -1, after gastroscopy examina-
tion, and then randomly assigned to one of three treat-
ment groups (three horses per treatment group) by
drawing numbers out of a hat: control (untreated), E-250
(125 gm, top-dressed on sweet feed, twice daily) and E-
SLH (50 gm, top-dressed on sweet feed, twice daily). For
period 2, horses were randomly assigned to the alternate
two treatment groups (three horses per treatment group)
by drawing a number out of a hat. For period 3, horses
were assigned to the treatment groups (three horses per
treatment group) that they had not been assigned to pre-
viously. The treatment groups were equal (n=3) for all
the treatment periods, including periods 2 and 3.
The experiment was performed as a three-period,
three-treatment crossover design. Horses were housed
in stalls and fed sweet feed (1 kg, twice daily, Omolene
100, Purina Mills, St. Louis, MO, USA). Horses were
also fed mixed grass hay (1.5% of body weight) divided
into two equal feedings per day. Horses served as their
own controls.
The day prior to the beginning of each period (Day-1),
horses were taken out of the pasture and housed in non-
environmentally controlled 3 m x 3 m stalls. Horses in
the treatment groups received E-250 or E-SLH top-
dressed on sweet feed twice daily during treatment peri-
ods, while control horses received the same amount of
sweet feed without supplement added. At the end of 21
days of treatment, horses were subjected to a modified
intermittent feed-deprivation protocol to cause or worsen
existing NG gastric ulcers [29]. Briefly, during the feed-
deprivation periods, horses were muzzled and deprived
of feed for 24 hours, then fed their normal ration for
24 hours until a total of 96 hours of cumulative feed-
deprivation was achieved. Horses were muzzled and
wood-shavings were removed from the stalls during the
feed-deprivation period to prevent ingestion of bedding
and manure. E-250 and E-SLH-treated horses continued
to receive treatment twice daily top-dressed on sweet
feed, while control horses received the same amount of
sweet feed without treatment. After each period, horses
were turned out in the pasture, where they were main-
tained on native grass pastures supplemented with native
round-bale grass hay for at least 2 weeks to prevent
carry-over treatment effects. Period 1 was 28 days in
length and periods 2 and 3 were 35 days in length. Peri-
ods 2 and 3 were lengthened to determine the effect of
treatment on recovery from the feed-deprivation model,
and each treatment group continued to have three
horses. In addition, a longer treatment for periods 2 and
3 was added, as a previous study in horses treated with
pectin and lecithin did not show a treatment effect until
after being treated for 30 days [20]. Horses had free
access to water at all times. After period 3 horses were
returned to the EHSP herd.
Gastroscopy was performed on all horses on days -1,
21, and 28 of treatment in period 1, and on days -1, 21,
28, and 35 of treatment in periods 2 and 3. Gastroscopic
examination was performed using a 3-m endoscope
(Karl Storz, El Segundo, CA, USA). To improve visuali-
zation of the stomach, feed was withheld for 16-18
hours and water for 3-4 hours prior to gastroscopy.
Horses were sedated with xylazine (0.4 mg/kg, IV;
AnaSed®, Lloyd, Shenandoah, IA, USA) prior to gastro-
scopic examination. To enable observation of the NG
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squamous mucosa (fundus ventriculi), margo plicatus,
and glandular mucosa (corpus ventriculi), the stomach
was insufflated with air using an air compressor (Air-
head® High Pressure Air Pump, Kwik Tek, Denver, CO,
USA) attached to the endoscope biopsy channel until the
rugae, or stomach folds, disappeared. The mucosa was
rinsed of adherent food material and mucus with tap
water flushed through the endoscope biopsy channel.
Each horse’s stomach was assigned an EGUS gastric ulcer
score by one of the authors (FMA) masked to treatment
groups, based on the EGUS ulcer scoring system where,
score 0 = Intact mucosa (can have reddening and/or
hyperkeratosis), score 1 = small single or small multifocal
ulcers, score 2 is large single or large multifocal ulcers,
and score 3 = extensive (often coalescing) ulcers with
areas of apparent deep ulceration [15]. In addition, gland-
ular ulcers were counted and recorded.
Gastric fluid was aspirated through the biopsy channel of
the endoscope prior to insufflation of the stomach or addi-
tion of tap water and pH was measured within 30 minutes
using a benchtop pH meter (ThermoOrion pH Meter
Model 410A, Thermo Fisher Scientific, Beverly, MA).
Venous blood samples were collected from the jugular
vein in heparinized blood gas syringes (Arterial Blood
Sampler, Radiometer Medical ApS, Brøshøj, Denmark), air
bubbles were expressed, the needle removed and syringe
capped, and immediately placed in ice. The blood gas sam-
ples were obtained from all horses on the first three days
of treatment Periods 1 and 3. Samples were collected prior
to treatment and 2, 6, 12 (before the second treatment),
24 (before the third treatment), and 48 hours (before the
fourth treatment) after treatment. These samples were
analyzed using an automated blood gas analyzer (Rapid-
point 405, Siemens, Norwood, MA) for bicarbonate con-
centration ([HCO3]), total carbon dioxide (TCO2) and
partial pressure of carbon dioxide (pCO2).
Data were pooled and means and standard error of the
means (SEM) were reported on all variables using the 35-
day values taken from horses completing periods 2 and 3.
Data were analyzed statistically using a statistical analysis
package for personal computers (SAS® 9.1, SAS Institute,
Inc., Cary, NC). A repeated measures analysis of variance
(ANOVA) using a mixed effects model (proc MIXED)
was used to analyze the data. Fixed effects in the model
included Treatment, Period and the interaction of Treat-
ment*Period. When significant differences were found,
post-hoc pairwise comparisons were conducted with t-
tests of least-squares means for main effects and for
interaction effects. Significant was set at P < 0.05.
Results
Physical examinations were within normal limits and
there was no evidence of clinical gastrointestinal disease
in any of the horses prior to enrollment in the study.
One horse entered the trial with a laceration over the
metacarpal III bone. This wound was routinely cleaned
and bandaged throughout the course of the study and
no medication was administered for the wound. Feed
quantities (hay) were adjusted so that body weight did
not change significantly during the trial. The amount of
hay required to maintain body weight was not evaluated
statistically.
E-250, a pelleted formulation, when mixed with sweet
feed, was readily consumed by all horses. E-SLH, a powder
formulation, when mixed with sweet feed, was consumed
by all horses, but some horses took several hours to con-
sume the product and the powder immediately sifted to
the bottom of the grain bucket when top-dressed.
One untreated horse and one E-250-treated horse
developed abdominal pain (colic) during period 1 and the
final day of period 3 of the study, respectively. In both of
these horses, clinical signs resolved with flunixin meglu-
mine (1.1 mg/kg, IV, once) and mineral oil (2 liters, via
nasogastric tube) administration.
A period effect was not noted.
Gastric ulcer scores
There was no significant difference in mean EGUS scores
between treatment groups on day 1, prior to beginning
the study. However, mean EGUS scores decreased signifi-
cantly (p<0.05) in the control group after 21 days of
treatment, when compared to day 1, but there was no dif-
ference in ulcer scores when compared to the Egusin®
treated horses on day 21. On day 28 of treatment, mean
EGUS scores significantly increased in the control and E-
250 groups, indicating that the feed-deprivation model
was effective in inducing or worsening gastric ulcers. In
addition, mean gastric ulcer scores did not significantly
increase in the Egusin SLH®-treated horses at day 28
when compared to day 21. However, there was no treat-
ment effect at this time point. By day 35 of treatment,
one week after the feed-deprivation period, mean EGUS
scores significantly decreased in the E-SLH- and E-250-
treated horses, when compared to untreated controls at
the same time point and scores on day 28 of the same
treatment group. Also, by day 35 of treatment, individual
EGUS scores either decreased or stayed the same in all
Egusin®-treated horses (Figure 1).
Glandular ulcers
Glandular ulcers were observed in 6/72 (8%) gastro-
scopic examinations performed in this study. There was
no significant day or day by treatment effect on the
number of glandular ulcers in this study.
Gastric fluid pH
Mean ± SEM gastric fluid pH, 2.76 ± 1.53 (range, 1.39-
8.0), aspirated just prior to gastroscopic examination,
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was low and variable in horses in this study. There was
no significant day or treatment effect on gastric juice
pH during the study period. On the mornings of evalua-
tion, the E-250 and E-SLH were not fed on the morn-
ings until after the horses underwent gastroscopy.
Blood gas values
[HCO3] did not significantly differ between days or
within treatment groups for the study. However, mean
pCO2 significantly increased 2 hours after initial treat-
ment on day 0 in both E-250- and E-SLH-treated horses,
when compared the untreated controls (Figure 2). Mean
TCO2 was significantly higher in the E-250- and E-SLH-
treated horses, 24 hours after treatment when compared
to the 12-hour samples (Figure 3). However, mean TCO2
did not differ significantly from controls or between
treatment groups throughout the rest of the treatment
period (Figure 3).
Discussion
The Egusin® products, when mixed with sweet feed,
were consumed by all horses. However, the E-250 (pellet
Figure 1 Gastric ulcer scores Mean ± SEM of Equine Gastric Ulcer Syndrome (EGUS) scores in horses fed Egusin 250® Supplement, Egusin SLH®
Supplement, and controls during periods two and three before treatment (Day -1), after 21 days of treatment (Day 21), after 28 days of
treatment (Day 28), and after 35 days of treatment (Day 35). A 7-day alternating feed-deprivation protocol was employed between Days 21 and
28. † Denotes a significant (P < 0.05) difference from scores from the previous week within a group and * denotes significant differences
(P < 0.05) from control values for the same week. (controls = red bar; E-250 = yellow bar; E-SLH = blue bar)
Figure 2 Partial pressure of CO2 Mean partial pressure of CO2 (pCO2) + SEM in whole heparinized venous blood in control, Egusin 250
®, and
Egusin SLH® treated horses before treatment (0), 2, 6, 12, 24, and 48 hours after treatment. * denotes a significant (P < 0.05) difference from
control values at the same time point. (controls = red line with diamonds; E-250 = yellow line with squares; E-SLH = blue line with triangles)
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formulation) was consumed more readily and comple-
tely than the E-SLH (powder formulation). The E-SLH
sifted to the bottom of the feed tub and took longer for
the horses to consume.
Two horses, an untreated control and E-250-treated
horse, had signs of abdominal pain (colic) during the
study. These horses were treated medically and recovered
completely. Abdominal pain is a common clinical sign of
gastric ulcers in horses and may have caused the signs
seen in these two horses as they both had ulcers in the
study. Although mineral oil and flunixin meglumine was
administered to these two horses during the study, the
authors feel that at the single dose administered, the
drugs did not interfere with the results. No other clinical
signs were noted in horses in this study.
Period one lasted for 28 days, while periods two and
three were extended for a further 7 days after the feed-
deprivation period (for a total of 35 days). This protocol
change was based on a lack of response within the first
28 days, as well as previous studies with products con-
taining pectin and lecithin and other ingredients that
demonstrated improved ulcer scores after 30 days of
treatment [18,20]. Thus, a 35-day, was incorporated into
the later periods (2 and 3) to allow time to adequately
evaluate the effects of treatment. In addition, statistical
analysis focused on gastric ulcers scores in the 6 horses
in each treatment group for these periods.
The intermittent feed-deprivation model used in this
study was successful in worsening existing NG gastric
ulcers, as mean EGUS scores significantly increased in
the untreated controls and in the E-250-treated group
after feed-deprivation. Egusin SLH® treated horses did
not show an increase in ulcer severity after feed-
deprivation, and at day 28, there was no difference
between control group and Egusin® treatments. How-
ever, after 35 days of treatment, in control horses, gastric
ulcer scores remained similar to day 28, while gastric
ulcer scores decreased significantly in both Egusin® -trea-
ted groups. Glandular ulcers were only seen in a few
horses and there was not treatment effect.
In the study reported here, there was a decrease in
mean EGUS gastric ulcer scores in the control horses
after 21 days of treatment, but the scores were not sig-
nificantly different from the other treatment groups at
the same time point. Previous studies have shown that
pasture-housed horses typically have less severe NG
ulcers than stall-confined horses [30]. However, in a
recent study, 71% of non-pregnant broodmares housed
at pasture had gastric ulcers and some were severe [31].
The exact reason for the decrease in gastric ulcer sever-
ity in control horses in the study reported here is
unknown, but might have been due to changes in man-
agement during this period. Typically, pasture grass in
Louisiana has poor nutritional quality during the late
fall and winter. The decreased feeding stress and
increased nutrition could have led to the decreased
severity of gastric ulcers in control horses during the
first 21 days of the study compared to day 1. However,
a similar decrease was not noted in the other treatment
groups. Unfortunately, a feed analysis was not per-
formed during the study period. During the study, horse
body weight was measured before each gastroscopic
examination and feed intake was adjusted to maintain
body weight.
Egusin®-treated horses had improved NG gastric ulcer
scores in this study after 35 days. The reason for the
Figure 3 Total CO2 Mean total CO2 (TCO2) + SEM in whole heparinized venous blood in control, Egusin 250
®, and Egusin SLH® treated horses
before treatment (0), 2, 6, 12, 24, and 48 hours after treatment. (†) denotes a significant (P < 0.05) difference in measurement from the previous
time within a group. (controls = red line with diamonds; E-250 = yellow line with squares; E-SLH = blue line with triangles)
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improvement in NG gastric ulcer scores might have
been due to the ingredients found in the supplements.
The Egusin® supplements used in this study contain
surface-active and antacid ingredients, of which the
amounts are proprietary. Surface-active ingredients
include pectin (dried apple pectin pulp), soy lecithin, ß-
glutan (micro-milled whole oats), whereas the antacids
include dehydrated alfalfa meal, calcium carbonate, and
sodium bicarbonate.
Pectin is a soluble complex polysaccharide derived from
the cell wall of fruits and vegetables. Lecithin is a phos-
pholipid derived from soybeans and is an emulsifying,
lubricating agent that has surfactant properties. Pectin acts
with lecithin to form a hydrophobic barrier on the gastric
mucosal membranes, protecting them against the corro-
sive effects of gastric acids. In horses, the surface of the
NG stomach is coated with dense osmophilic surface-
active phospholipids (SAPLs), similar to the structure of
pulmonary surfactant [32]. These hydrophobic SAPLs
might provide the primary defense mechanism against
exposure to hydrochloric and other organic acids found in
gastric fluid. Feed additives containing pectin and lecithin
have been previously evaluated in horses with gastric
ulcers and the results have been mixed [19,20,33]. Egusin®
(which contains a proprietary mixture of pectin and
lecithin) treatment significantly decreased NG gastric
ulcer severity, when compared to untreated control horses,
but there was not a treatment effect until day 35. In two
previous studies, pectin and lecithin containing supple-
ments decreased NG gastric ulcer severity after 10 days
[33] and after 30 days [20] of treatment. Results in the
later study, where horses were fed for 30 days, were similar
to data in the study presented here, where it took 35 days
to see a treatment effect in the Egusin®-treated horses.
However in another study, pectin and lecithin-treat-
ment failed to prevent NG gastric ulcers from worsening
after a 96-hour feed-deprivation period [19]. The results
from that study were similar to the results from the study
presented here, where Egusin 250® treatment failed to
prevent NG gastric ulcers from worsening during the
feed-deprivation period[19]. However, E-SLH prevented
the worsening of NG gastric ulcers during the period of
feed-deprivation, but there was no treatment effect at day
28, when Egusin SLH® was compared to the other treat-
ment groups. Therefore the results should not be over
interpreted as a response to treatment. It should be
noted, however, that Egusin SLH® has a higher concen-
tration of pectin and lecithin and other ingredients than
Egusin 250®, which could have accounted for this effect.
In addition to surface acting phospholipid compounds,
Egusin® products contain buffering agents, including cal-
cium carbonate and sodium bicarbonate, which are com-
monly used used in people and horses to buffer stomach
contents and neutralize gastric juice pH. No studies have
critically evaluated the effects of antacids on gastric ulcer
scores in horses. However, calcium carbonate reversed
the damaging effects of hydrochloric acid on sodium and
chloride transport across the NG mucosa in an in vitro
Ussing chamber model [27,28]. In addition, one of the
authors (FMA) showed that a supplement (Neigh-Lox®,
Kentucky Performance Products, LLC, Versailles, KY)
containing calcium carbonate fed to horses for 30 days
increased gastric juice pH for 2 hours after feeding, but
failed to improve gastric ulcer scores (unpublished data,
Frank M. Andrews). This is similar to previous studies
where antacids increase gastric juice pH for approxi-
mately 2 hours after administration [34]. Unfortunately,
gastric juice pH was not measured two hours after feed-
ing in the horses in the study. In addition to calcium car-
bonate, Egusin® also contains sodium bicarbonate, which
is not commonly used to treat gastric ulcers in horses
and has not been critically evaluated for that purpose.
However, it may increase gastric juice pH. In addition,
sodium bicarbonate, when fed orally, can effect on blood
pH. Sodium bicarbonate “milkshakes” have been gener-
ally speculated to help racing horses by increasing the pH
of the blood, buffering lactic acid, and delaying onset of
fatigue in muscles [35]. The generally accepted level of
TCO2 in Thoroughbred racing in the United States is
below 37 mmol/l [36]. Values that exceed 37 mmol/l are
considered doping. The mean TCO2 values in the horses
in this study did not exceed 37 mmol/l, despite the pre-
sence of calcium carbonate and sodium bicarbonate in
the supplements. However, it is unlikely that the sodium
bicarbonate concentration found in the Egusin® products
exceeds 0.5 g/kg, which has been shown to cause the
blood TCO2 to increase above doping values.
The other ingredient that might have provided some
buffering capacity is dried alfalfa meal. Although there
are no studies evaluating the use of dried alfalfa meal in
horses with gastric ulcers, horses fed alfalfa hay had
higher gastric juice pH and lower NG gastric ulcer scores
than the same horses fed bromegrass hay [37]. In another
study, horses exercised and fed alfalfa hay had less severe
NG gastric ulcers than horse that were fed grass hay [38].
It was hypothesized that the calcium carbonate in the
alfalfa hay buffered stomach acid or directly inhibited
gastric acid secretion as has been shown in rats fed diets
containing 2% calcium carbonate [38]. It is unlikely that
the concentration of calcium carbonate found in the
dried alfalfa meal found in Egusin® would be equivalent
to that found in baled alfalfa hay, therefore its effect is
likely minimal.
Gastric fluid pH was generally low and variable but not
significantly different in Egusin® treated horses when
compared to untreated controls. Gastric fluid pH can be
affected by stomach contents and the location in which
the sample was taken [39]. A single sample aspirated
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from the stomach of horses can be variable and might
not as accurate as continuous monitoring with a pH
probe. However, gastric juice pH in the study reported
here was similar to measurements where samples were
collected via gastric cannulae and by continuous moni-
toring [18,37,40]. Neither Egusin® product significantly
altered gastric fluid pH at the times measured. However,
perhaps a significant difference might have been seen if
sampling would have been obtained within 2 hours of
treatment, but may not have had a significant effect on
gastric ulcer healing.
Other nutritional ingredients found in these Egusin®
products may have decreased NG gastric ulcer scores in
these horses. ß-glucan has been shown to form gels in
the stomach of other species and acts to coat the sto-
mach lining. Studies in rats have shown antiulcergenic
effects of ß-(1–>3)-glucosyl-linkage on beta-1–>3)-glu-
can itself is an important part of the active principle for
anti-ulcerogenesis [41]. Studies on the effects of ß-glucan
have not been reported in horses, but may be similar to
those seen in rats. Also, the polar lipids in these supple-
ments are a rich source of phospholipids and aid in re-
establishing the stomach lining. However, there are no
studies reported in horses on the effect of polar lipids on
gastric ulcer scores in horses.
Conclusions
The results of this study confirm that stall-confined
horses undergoing feed-deprivation have a significant
increase in the severity of NG gastric ulcers. However, it
should be noted that a change in management from pas-
ture to stall confinement and regular feeding could lower
NG gastric ulcer scores in horses. Control horses had sig-
nificantly decreased gastric ulcer scores after 21 days of
stall-confinement, but these values were not different
from the other treatment groups. Based on the data
reported here, it appears that the ingredients contained
in Egusin 250® were not effective in reducing gastric
ulcer severity during feed-deprivation, whereas the simi-
lar ingredients in Egusin SLH®, which are higher in con-
centration than Egusin 250®, may have aided in blunting
an increase in NG gastric severity during feed-depriva-
tion, although gastric ulcer scores increased in all treat-
ment groups. Futhermore, gastric ulcer scores decreased
in both Egusin® -treated groups after 35 days of feeding
(7 days after feed-deprivation). Thus, Egusin® supple-
ments fed twice daily for 35 days might reduce gastric
ulcers scores after feed stress without exceeding thresh-
old concentrations of bicarbonate.
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